2016 ESC Position Paper on Cancer Treatments and Cardiovascular Toxicity Developed Under the Auspices of the ESC Committee for Practice Guidelines
José Luis Zamorano, Patrizio Lancellotti, Daniel Muñoz, Victor Aboyans, Riccardo Asteggiano, Maurizio Galderisi, Gilbert Habib, Daniel J. Lenihan, Gregory Y.H. Lip, Alexander R. Lyon, Teresa López‐Fernández, Dania Mohty, Massimo Piepoli, Juan Tamargo, Adam Torbicki, Thomas Suter, José Luis Zamorano, Victor Aboyans, Stephan Achenbach, Stefan Agewall, Lina Badimón, Gonzalo Barón‐Esquivias, Helmut Baumgartner, Jeroen J. Bax, Héctor Bueno, Scipione Carerj, Veronica Dean, Çetin Erol, Donna Fitzsimons, O. Gaemperli, Paulus Kirchhof, Philippe Kolh, Patrizio Lancellotti, Gregory Y.H. Lip, Petros Nihoyannopoulos, Massimo Piepoli, Piotr Ponikowski, Marco Roffi, Adam Torbicki, António Vaz Carneiro, Stephan Windecker, Marco Roffi, Adam Torbicki, António Vaz Carneiro, Stephan Windecker
Abstract
... ... Guidelines and position papers written under the auspices of the ESC Committee for Practice Guidelines (CPG) summarize and evaluate all available evidence on a particular issue at the time of the writing process, with the aim of assisting health professionals in selecting the best management strategies for an individual patient with a given condition, taking into account the impact on outcome, as well as the risk–benefit ratio of particular diagnostic or therapeutic means. CPG Guidelines and position papers should help health professionals to make decisions in their daily practice. However, the final decisions concerning an individual patient must be made by the responsible health professional(s) in consultation with the patient and caregiver as appropriate. Members of this Task Force were selected by the ESC to represent professionals involved with the medical care of patients with this pathology. Selected experts in the field undertook a comprehensive review of the published evidence for management (including diagnosis, treatment, prevention and rehabilitation) of a given condition according to CPG policy. A critical evaluation of diagnostic and therapeutic procedures was performed, including assessment of the risk–benefit ratio. Estimates of expected health outcomes for larger populations were included, where data exist.